Organon (OGN) Short-term Investments (2023 - 2024)
Organon (OGN) recorded quarterly Short-term Investments of $29.0 million in Q4 2024, up 222.22% quarter-over-quarter from $9.0 million in Q4 2023, and up 222.22% on a YoY basis from $9.0 million in Q1 2024.
Organon (OGN) Short-term Investments (2023 - 2024) Analysis & Trends
Organon's Short-term Investments history runs 2 years deep, the most recent figure standing at $29.0 million for Q4 2024.
- In Q4 2024, Short-term Investments rose 222.22% year-over-year to $29.0 million; the TTM figure through Dec 2024 stood at $29.0 million (up 222.22% YoY), while the FY2024 annual figure was $29.0 million, up 222.22% from the prior year.
- Short-term Investments was $29.0 million for Q4 2024 at Organon, up from $9.0 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $29.0 million in Q4 2024 to a low of $9.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 29.00 Mn |
| Dec 31, 2023 | 9.00 Mn |